On Invalid Date, Crispr Therapeutics Ag (NASDAQ: CRSP) reported Q1 2024 earnings per share (EPS) of -$1.43, up 113.43% year over year. Total Crispr Therapeutics Ag earnings for the quarter were -$116.59 million. In the same quarter last year, Crispr Therapeutics Ag's earnings per share (EPS) was -$0.67.
As of Q2 2024, Crispr Therapeutics Ag's earnings has grown year over year. Crispr Therapeutics Ag's earnings in the past year totalled -$217.14 million.
What was CRSP's revenue last quarter?
On Invalid Date, Crispr Therapeutics Ag (NASDAQ: CRSP) reported Q1 2024 revenue of $504.00 thousand up 99.5% year over year. In the same quarter last year, Crispr Therapeutics Ag's revenue was $100.00 million.
What was CRSP's revenue growth in the past year?
As of Q2 2024, Crispr Therapeutics Ag's revenue has grown 171.01% year over year. This is 93.78 percentage points higher than the US Biotechnology industry revenue growth rate of 77.23%. Crispr Therapeutics Ag's revenue in the past year totalled $271.71 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.